Volume 22, Issue 2 (Pajouhan Scientific Journal, Spring 2024)
Pajouhan Sci J 2024, 22(2): 164-172 |
Back to browse issues page
Ethics code: IR.UMSHA.REC.1401.113
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirmoeini E S, Mirmoeini R S, Khazaei S, Karimi S, Zamani R, Sa'ati M H. Intelligence Quotient and Its Affected Epidemiological Factors in Children with Phenylketonuria in Hamadan Province. Pajouhan Sci J 2024; 22 (2) :164-172
URL: http://psj.umsha.ac.ir/article-1-1070-en.html
URL: http://psj.umsha.ac.ir/article-1-1070-en.html
Effat Sadat Mirmoeini * 
1, Razieh Sadat Mirmoeini2 , Salman Khazaei3 , Simin Karimi4 , Reza Zamani2 , Mohammad Hasan Sa'ati5
1, Razieh Sadat Mirmoeini2 , Salman Khazaei3 , Simin Karimi4 , Reza Zamani2 , Mohammad Hasan Sa'ati5
1- Clinical Research Development Unit, Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran , emirmoeini@hotmail.com
2- Center for Disease Control and Prevention, Vice-Chancellor of Health, Hamadan University of Medical Sciences, Hamadan, Iran
3- Research Center for Health Sciences, Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran
4- Hereditary-Metabolic Diseases Clinic, Vice-Chancellor of Health, Hamadan University of Medical Sciences, Hamadan, Iran
5- Be'sat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran
2- Center for Disease Control and Prevention, Vice-Chancellor of Health, Hamadan University of Medical Sciences, Hamadan, Iran
3- Research Center for Health Sciences, Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran
4- Hereditary-Metabolic Diseases Clinic, Vice-Chancellor of Health, Hamadan University of Medical Sciences, Hamadan, Iran
5- Be'sat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (834 Views)
Background and Objectives: Phenylketonuria (PKU) is a rare hereditary metabolic disease caused by the phenylalanine hydroxylase enzyme (PAH) deficit. Delays in diagnosis and treatment have serious effects on the nervous system and reduce the IQ of these children.
Materials and Methods: The current cross-sectional study was conducted on 55 children aged 5 to 18 years with a definite diagnosis of PKU who were taken care of in the Genetic Diseases Control Center, Hamadan Be'sat Hospital. The information of the patients was obtained from the file and interviews with the parents and then recorded in the checklist. For individual measurement of cognitive abilities and IQ, the Stanford Binet Questionnaire was used, and statistical analyses were performed in Stata 16 software.
Results: The average age of the children was 11.08 years,52.73% of the samples were children of consanguineous marriage parents, and 29.09% had a history of PKU in the family. The average age of diagnosis was 15.09 months. The disease had been diagnosed in 47% of cases by screening. The IQ of 3.5% of the children was normal, 42% was low average, 43.5% had borderline much lower than average, and 11% suffered from mental retardation. The average age of diagnosis was 5, 15, 13, and 27.5 months, respectively. A significant relationship was found between IQ and the child's age and birth order (P<0.05), disease diagnosis through screening (P=0.009), incidence of failure to thrive disorder (P=0.006), and incidence of specific developmental disorder (P=0.002).
Conclusion: Early diagnosis and treatment of PKU by screening have an important role in preventing mental retardation. Higher birth order and increasing age are associated with a decrease in IQ; therefore, periodic assessment of IQ is necessary for the educational planning of these patients.
Materials and Methods: The current cross-sectional study was conducted on 55 children aged 5 to 18 years with a definite diagnosis of PKU who were taken care of in the Genetic Diseases Control Center, Hamadan Be'sat Hospital. The information of the patients was obtained from the file and interviews with the parents and then recorded in the checklist. For individual measurement of cognitive abilities and IQ, the Stanford Binet Questionnaire was used, and statistical analyses were performed in Stata 16 software.
Results: The average age of the children was 11.08 years,52.73% of the samples were children of consanguineous marriage parents, and 29.09% had a history of PKU in the family. The average age of diagnosis was 15.09 months. The disease had been diagnosed in 47% of cases by screening. The IQ of 3.5% of the children was normal, 42% was low average, 43.5% had borderline much lower than average, and 11% suffered from mental retardation. The average age of diagnosis was 5, 15, 13, and 27.5 months, respectively. A significant relationship was found between IQ and the child's age and birth order (P<0.05), disease diagnosis through screening (P=0.009), incidence of failure to thrive disorder (P=0.006), and incidence of specific developmental disorder (P=0.002).
Conclusion: Early diagnosis and treatment of PKU by screening have an important role in preventing mental retardation. Higher birth order and increasing age are associated with a decrease in IQ; therefore, periodic assessment of IQ is necessary for the educational planning of these patients.
Type of Study: Research Article |
Subject:
Medicine & Clinical Sciences
Received: 2023/11/20 | Accepted: 2024/06/5 | Published: 2024/07/31
Received: 2023/11/20 | Accepted: 2024/06/5 | Published: 2024/07/31
References
1. Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. The Lancet. 2010;376(9750):1417-27. [DOI:10.1016/S0140-6736(10)60961-0] [PMID]
2. Thiele AG, Gausche R, Lindenberg C, Beger C, Arelin M, Rohde C, Mütze U, Weigel JF, Mohnike K, Baerwald C, Scholz M. Growth and final height among children with phenylketonuria. Pediatrics. 2017;140(5). [DOI:10.1542/peds.2017-0015] [PMID]
3. Farhud D, Shalileh M. Phenylketonuria and its dietary therapy in children. 2008.
4. Luciana M, Sullivan J, Nelson CA. Associations between phenylalanine‐to‐tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Development. 2001;72(6):1637-52. [DOI:10.1111/1467-8624.00370] [PMID]
5. Sadek AA, Hassan MH, Mohammed NA. Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years. Neuropsychiatric disease and treatment. 2018;14:2551. [DOI:10.2147/NDT.S176198] [PMID]
6. Bartus A, Palasti F, Juhasz E, Kiss E, Simonova E, Sumanszki C, et al. The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients. Metab Brain Dis. 2018;33(5):1609-15. [DOI:10.1007/s11011-018-0267-6] [PMID]
7. Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Molecular Genetics and Metabolism. 2007;92(1-2):63-70. [DOI:10.1016/j.ymgme.2007.05.006] [PMID]
8. Saadatinasab Z, Sharifzadeh G. Incidence of phenylketonuria in southern Khorasan (2012-2014). J Birjand Univ Med Sci. 2015;22(3):286-92.
9. Ghiasvand N, Aledavood A, Ghiasvand R, Seyedin Borojeny F, Aledavood A, Seyed S, et al. Prevalence of classical phenylketonuria in mentally retarded individuals in Iran. Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism. 2009;32:283-7. [DOI:10.1007/s10545-009-1222-9] [PMID]
10. Huijbregts S, De Sonneville L, Licht R, Van Spronsen F, Verkerk P, Sergeant J. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 2002;40(1):7-15. [DOI:10.1016/S0028-3932(01)00078-1] [PMID]
11. Anastasoaie V, Kurzius L, Forbes P, Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Molecular genetics and metabolism. 2008;95(1-2):17-20. [DOI:10.1016/j.ymgme.2008.06.014] [PMID]
12. Roid GH, Pomplun M. The stanford-binet intelligence scales: The Guilford Press. 2012.
13. Jafari A. Psychometric Properties of The Revised Version Tehran-Stanford-Binet Intelligence Scale in Diagnosis Children with Specific Learning Disability. JOEC. 2020; 20(1):129-140.
14. Motamedi N, Goodarzi E, Pordanjani SR, Valizadeh R, Moradi Y, Sohrabivafa M, et al. Incidence of phenylketonuria in Lorestan province, West of Iran (2006-2016). International Journal of Pediatrics-Mashhad. 2017;5:4713-21.
15. Badiee S, Morovatdar N, Hossini SMR, Norouzi F, Mina T. Epidemiological and clinical study of phenylketonouria (PKU) disease in Khorasan Province ; Northeast Iran. Medical Journal of Mashhad university of Medical Sciences. 2014;57(3):571-8.
16. Vela-Amieva M, Ibarra-González I, Fernández-Lainez C, Monroy-Santoyo S, Guillén-López S, Belmont-Martínez L, et al. Causes of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico. Journal of medical screening. 2011;18(3):115-20. [DOI:10.1258/jms.2011.011028] [PMID]
17. Rodrigues C, Pinto A, Faria A, Teixeira D, van Wegberg AM, Ahring K, et al. Is the Phenylalanine-Restricted Diet a Risk Factor for Overweight or Obesity in Patients with Phenylketonuria (PKU)? A Systematic Review and Meta-Analysis. Nutrients. 2021;13(10):3443. [DOI:10.3390/nu13103443] [PMID]
18. Keramati N, Soleymani Z, Rouhani F, Jalaie S, Alaee MR. The effect of the age of treatment onset and quality of dietary control on language and intelligence functions in patients with Phenylketonuria. Bimonthly Audiology-Tehran University of Medical Sciences. 2013;22(3):42-51.
19. González MJ, Gutiérrez AP, Gassió R, Fusté ME, Vilaseca MA, Campistol J. Neurological complications and behavioral problems in patients with phenylketonuria in a follow-up unit. Molecular genetics and metabolism. 2011;104:S73-9. [DOI:10.1016/j.ymgme.2011.07.015] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences.
Published by UMSHA Press
Journal Tel: +98 81 38380090
Publisher Tel: +98 81 38382022
Website: https://psj.umsha.ac.ir/
Email: psj@umsha.ac.ir
